总投资120亿？这家企业两个基地规划布局46万阿洛酮糖

Core Viewpoint - The article discusses the recent approval of a large-scale D-alloheptulose sugar production project by Hubei Ganyuan Biotechnology Co., Ltd., highlighting the investment and infrastructure development in the biomanufacturing sector [2][3]. Group 1: Project Overview - Hubei Ganyuan Biotechnology Co., Ltd. has received approval for a project to produce 400,000 tons of D-alloheptulose sugar annually, with a total investment of 11 billion yuan [2]. - The project will cover an area of 1,500 acres and is expected to commence construction in December 2025, featuring a building area of approximately 50,000 square meters [2]. - The facility will include various automated systems and production lines, such as fructose isomerization systems and crystallization systems, to enhance production efficiency [2]. Group 2: Company Background - Hubei Ganyuan Biotechnology Co., Ltd. was established on August 15, 2025, with a registered capital of 5 million yuan, focusing on the development of biological feed, food additives, and health food sales [3]. - An associated company, Liaoning Ganyuan Biotechnology Co., Ltd., was founded on April 8, 2025, with a registered capital of 150 million yuan, primarily engaged in food additives and production [5]. Group 3: Environmental Impact and Additional Projects - The environmental assessment for Liaoning Ganyuan's 60,000 tons D-alloheptulose project has been approved, with an investment of 1 billion yuan, utilizing glucose syrup as a raw material [6][7]. - The project aims to produce both D-alloheptulose syrup and potentially crystalline products based on market demand [7].